Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + everolimus for relapsed unresectable or metastatic high-grade osteosarcoma
2011-000561-12Phase 2Completed
- Sponsor
- Italian Sarcoma Group
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and everolimus in osteosarcoma (OS), sponsored by Italian Sarcoma Group. Primary endpoint: Progression-free survival at 6 months. Started Jan 2012; status: completed.
02
Drugs
sorafenibeverolimus
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2011-000561-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000561-12.